Search Within

Carol A Aghajanian

Formats
  1. Journal Article (325)
  2. Meeting Abstract (284)
  3. Review (3)
  4. Book Section (1)
  5. Correspondence (1)
  6. Editorial (1)
Groups
  1. Department of Medicine (615)
  2. GDMT, Medicine (615)
  3. Gynecologic Medicine Service (615)
  4. Gynecology Disease Management Team (615)
  5. Solid Tumor Oncology Division (615)
  6. Surgery (229)

More Groups

People
  1. Nadeem Abu-Rustum (126)
  2. Paul Sabbatini (125)
  3. Alexia Iasonos (116)
  4. David Spriggs (105)
  5. Roisin O'Cearbhaill (99)
  6. Martee Hensley (94)

More People

Years
  1. 2025 (24)
  2. 2024 (38)
  3. 2023 (42)
  4. 2022 (45)
  5. 2021 (35)
  6. 2020 (61)

More Years

Publications
  1. Gynecologic Oncology (200)
  2. Journal of Clinical Oncology (150)
  3. International Journal of Gynecological Cancer (57)
  4. Clinical Cancer Research (30)
  5. Annals of Oncology (28)
  6. Cancer (15)

More Publications

Publishers
  1. Elsevier B.V. (204)
  2. American Society of Clinical Oncology (156)
  3. Lippincott Williams & Wilkins (59)
  4. American Association for Cancer Research (54)
  5. Oxford University Press (30)
  6. Elsevier Inc. (21)

More Publishers

Results (615)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study
    Journal Article

    Westin, S. N.; Sill, M. W.; Coleman, R. L.; Waggoner, S.; Moore, K. N.; Mathews, C. A.; Martin, L. P.; Modesitt, S. C.; Lee, S.; Ju, Z.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study
    Journal Article

    O'Cearbhaill, R. E.; Deng, W.; Chen, L. M.; Lucci, J. A. 3rd; Behbakht, K.; Spirtos, N. M.; Muller, C. Y.; Benigno, B. B.; Powell, M. A.; Berry, E.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer
    Journal Article

    Cadoo, K. A.; Mandelker, D. L.; Mukherjee, S.; Stewart, C.; DeLair, D.; Ravichandran, V.; Srinivasan, P.; Hurley, D.; Kemel, Y.; Arnold, A. G.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • A phase 2 study of TPIV200/ huFR-1 (a multi-epitope folate receptor alpha vaccine) in combination with durvalumab in patients with platinum resistant ovarian cancer
    Meeting Abstract

    Zamarin, D.; Yeku, O.; O'Cearbhaill, R. E.; Cadoo, K. A.; Gallagher, J.; Kravetz, S.; McDonnell, A.; Troso-Sandoval, T.; Sabbatini, P.; Lichtman, S.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Activity of M3814, an oral DNA-PK inhibitor, in combination with topoisomerase II inhibitors in ovarian cancer models
    Journal Article

    Wise, H. C.; Iyer, G. V.; Moore, K.; Temkin, S. M.; Gordon, S.; Aghajanian, C.; Grisham, R. N.
    Scientific Reports (2019)

    Fulltext@MSK | Save
  • Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers
    Meeting Abstract

    Cowan, R.; Pedra Nobre, S.; Zhou, Q.; Iasonos, A.; Long Roche, K.; Gardner, G.; Abu-Rustum, N.; Aghajanian, C.; Cadoo, K.
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent ovarian cancer: Final results
    Meeting Abstract

    Grisham, R.; Giri, D.; Henson, M.; Iasonos, A.; Zhou, Q.; McDonnell, A.; Girshman, J.; O'Cearbhaill, R.; Zamarin, D.; Aghajanian, C.
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • MILO/ENGOT-ov11: Phase-3 study of binimetinib versus physician's choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
    Meeting Abstract

    Grisham, R.; Monk, B. J.; Banerjee, S.; Coleman, R. L.; Oza, A. M.; Oehler, M. K.; Kalbacher, E.; Mirza Raza, M.; del Campo, J. M.; Marth, C.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Exploratory analysis of postprogression and patient-centered outcomes in ARIEL3: A phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma
    Meeting Abstract

    Coleman, R.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)
    Meeting Abstract

    Coleman, R. L.; Fleming, G. F.; Brady, M. F.; Swisher, E.; Steffensen, K. D.; Friedlander, M.; Okamoto, A.; Moore, K.; Ben-Baruch, N.; Werner, T. L.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save